Mutant strain of Brucella bacterin with weak poison, constructing method, and application

Abstract

This invention discloses attenuated Brucella mutant, its construction method and its application. The attenuated Brucella mutant is constructed by deleting bp26, wboA, omp31, and P39 or pgm gene from attenuated Brucella. It is proven by experiments that attenuated Brucella mutant has good immune protection effects and the same virulence as attenuated Brucella. Because certain antigen is delected in the attenuated Brucella mutant, vaccine immunity and natural infection can be differentiated according to the immunobiology of the deleted gene. The attenuated Brucella mutant can be used to manufacture preventative Brucella vaccine and marked attenuated vaccine, and prevent epidemic diseases caused by Brucella.

Description

technical field [0001] The invention relates to a vaccine mutant and its construction method and application, in particular to a Brucella attenuated vaccine mutant, its construction method and its application in preparing a Brucella preventive vaccine. Background technique [0002] Brucellosis (brucellosis) is a widespread and extremely harmful zoonotic disease caused by Brucella. Class II infectious diseases, and listed as the first class II infectious diseases recorded in the "Implementation Rules of the Regulations on Epidemic Prevention of Livestock and Poultry". So far, the disease has spread to five continents in the world, and there are more than 160 countries and regions in more than 200 countries and regions. Brucellosis is one of the most widespread and harmful zoonotic diseases in the world, seriously affecting people's health and the development of animal husbandry. When people suffer from this disease, the disease period can be as long as several months, sever...

AI Technical Summary

Problems solved by technology

[0003] The main problem of Brucella attenuated live vaccines in preventing and treating brucellosis between humans and animals is that the antibodies produced after vaccination cannot be distinguished from those produced by natural infection, which brings difficulties to the diagnosis of brucellosis

However, recent literature reports that RB51 also produces low levels of O-antigen, which means that the use of RB51 as a vaccine still has the possibility of interfering with routine serology and ELISA diagnosis (Cloeckaert A, Zygmunt M S, Guilloteau L A. Brucella abortus vaccine strain RB51 produces low levels of M-like O-antigen. Vaccine. 2002, 20: 1820-1822.)

Images